Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Jan 31:4:6.
doi: 10.21037/tgh.2019.01.06. eCollection 2019.

How to better select patients with advanced gastric cancer for immunotherapy

Aziz Zaanan  1   2   3 , Julien Taieb  1   2   3
Affiliations
Editorial

How to better select patients with advanced gastric cancer for immunotherapy

Aziz Zaanan et al. Transl Gastroenterol Hepatol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: A Zaanan has participated in consulting and/or advisory boards for Roche, Merck Serono, Amgen, Sanofi, Servier and Lilly. J Taieb has received honoraria for speaker and/or advisory role from Merck, Roche, Amgen, Eli Lilly, Sanofi, Celgene, Servier, and Sirtex.

Comment on

References

    1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018;359:1350-5. 10.1126/science.aar4060 - DOI - PMC - PubMed
    1. Fuchs CS, Doi T, Jang RW, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol 2018;4:e180013. 10.1001/jamaoncol.2018.0013 - DOI - PMC - PubMed
    1. Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015;372:2509-20. 10.1056/NEJMoa1500596 - DOI - PMC - PubMed
    1. Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 2018;24:1449-58. 10.1038/s41591-018-0101-z - DOI - PubMed
    1. Bang YJ, Ruiz EY, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol 2018;29:2052-60. 10.1093/annonc/mdy264 - DOI - PMC - PubMed